News & Events

Philogen to attend the Antibody Engineering & Therapeutics on December 12-16 , 2021

Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site. The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis factor) fused to the L19 antibody, specific to the alterantively-spliced EDB domain of fibronectin. In the seminar, Dario Neri is presenting the discovery and development of Tripokin towards clinical trials in patients with different types of cancer.

See antibody-engineering-therapeutics website for more details.